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1. Introduction
   For the past decade researches have been conducted in 
laboratories to better understand the biology and potential 
therapies of Ebola virus (EBOV)[1]. However, field based 
research in high risk populations such as impoverished villages 
much progress has not been accomplished. For instance, there 
have been outbreaks in the Democratic Republic of Congo in 
2007, 2008 and in Uganda in 2007[2].
   The EBOV belongs to the Filoviridae family[3] which affects 
both human and non-human primates (NHPs), causing severe 
hemorrhagic fever syndrome. The disease is characterized with 
symptoms and signs of fever, focal necrosis of the liver, kidney 
and spleen bleeding diathesis, fulminant shock resulting in death 
with a mortality rate reaching 90%[4,5]. The first two outbreak of 
the EBOV included illnesses such as fever, headache, vomiting 
and diarrhea. Nonetheless, during the early diagnosis of the 
EBOV, hemorrhagic manifestations were the most prominent 
features seen in patients who died[6]. The Filoviridae consist of 
three general names known as EBOV, Marburg virus (MARV) 
and Cuevavirus[7]. The disease is also considered to be a 
category A agent and potential bio-weapon agent[8].
   The first outbreak of an unknown infectious disease (Marburg 
disease) was reported in Germany and Yugoslavia in the year 
1967. An estimated 31 persons were affected in which 7 persons 
died. Eventually, a new strand of the virus was extracted from 
a patient and was traced back to velvet monkey imported from 
Uganda. The disease was named the ‘Marburg disease’ because 
it was located in the West German town of Marburg[9]. 
   In 1976, an occurrence of hemorrhagic fever started to spread 
rapidly in Sudan and Zaire with tremendous level of deaths. 
Specimens were isolated from patients and tested which revealed 
that the virus resembled the MARV but had different reactive 
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properties[9].
   This  paper aims to review various researches done, 
developments and progress made concerning the EBOV over the 
past several years. 
2. Epidemiology
   The EBOV has a case fatality rate of 30% to 90% and 
increased frequency in the African region due to weaker health 
infrastructure and services. The EBOV is sub-divided into five 
species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), 
Tai forest ebolavirus, Bundibugyo ebolavirus (BDBV), and 
Reston ebolavirus (REBOV)[10]. After the first case of the virus 
was discovered in 1967 in Germany, it appeared in Africa, two 
neighboring locations: Sudan and Zaire (SEBOV and ZEBOV), 
now in the Democratic Republic of the Congo[11]. Finally, it was 
named the EBOV after a small river located in the northwestern 
region of the Democratic Republic of Congo[12]. The third strain 
of the virus was discovered in 1994 and it was called the Cote 
d’Ivoire EBOV which was noted in the Tai forest[13]. The fourth 
strain of the virus was found in the equatorial Africa and it was 
called the BDBV[14]. Additionally, the last virus species was 
discovered in the Philippines and it was named the REBOV. 
The EBOV continues to be a plague for the occupants of West 
Africa, with increasing number of outbreaks seen in 2000[5]. The 
ZEBOV, SEBOV and BDBV has caused the most tremendous 
outbreak in sub-Saharan Africa. There have been outbreaks of the 
EBOV in countries such as Uganda, Sudan, Gabon, Democratic 
Republic of Congo and the Republic of Congo[15].Moreover, 
the emergence of the REBOV found in pigs raises public health 
concerns and food safety in the Philippines and can become 
a major problem in the near future[5]. The first few cases of 
the EBOV in Zaire occurred among factory workers and the 
reservoir animal host was unknown[6]. Eventually, an experiment 
conducted in the regions of Gabon and the Republic of Congo, 
suggested that fruit bats are believed to be the reservoir for 
EBOV[16]. And it is transferred to other hosts such as humans 
and gorillas[17]. Additional host of the virus are small rodents, 
duikers, NHPs and shrews. The current outbreak in Guinea, 
Liberia Sierra Leone and Nigeria showed that the greatest mode 
of contracting the virus is human to human transmission[18].
   The virus is highly contagious which is transmitted to 
individuals in direct contact with bodily fluids from an infected 
person[19]. The risk of transmission is highest during the latent 
stage of the disease but the level of transmission decreases during 
the early stages even if there is a high risk exposure[6]. Persons 
that are at the greatest risk for infection of the EBOV during an 
outbreak are, scientists[20], health care workers, relatives and 
those in close contact with ill individuals and deceased patients. 
Basic hygienic practices can be cultivated in the prevention of the 
EBOV such as regular washing of hands and changing of attire 
before and after getting in contact with these animals. Moreover, 
the consumption of sick animals should be avoided[18].
   Looking at the 2014 EBOV disease (EVD) outbreak in West 
Africa, as of September 14, 2014, a total of 4 507 probable 
and confirmed cases, including 2 296 deaths from EVD (Zaire 
species) had been reported from five countries in West Africa: 
Guinea, Liberia, Nigeria, Senegal and Sierra Leone. The World 
Health Organization Ebola Response Team analyzed a detailed 
subset of data on 3 343 confirmed and 667 probable Ebola cases 
collected from the five countries and found out that the majority 
of the patients are 15-44 years of age with 49% male. The case 
fatality rate was estimated at 70.8% (95% CI, 69-73) among 
persons with known clinical outcome of infection. The course 
of infection, including signs and symptoms, incubation period 
(11.4 d) and serial interval (15.3 d), is similar to that reported in 
previous outbreaks of EVD. Assuming no change in the control 
measures for this epidemic, the team projected that by November 
2, 2014, the cumulative reported numbers of confirmed and 
probable cases will be 5 740 in Guinea, 9 890 in Liberia and 5 000 
in Sierra Leone, exceeding 20 000 in total[21].
   In the 2014 outbreak, the World Health Organization conducted 
a virological analysis to determine if there was any linkage 
between the EBOV in West Africa and the Democratic Republic 
of Congo. The epidemiological investigation and results 
concluded that the outbreaks in the Democratic Republic of 
Congo were completely separate and independent event from the 
cases reported in West Africa. The finding reassures investigators 
that the virus has not spread from West to Central Africa[22]. 
However, investigators have isolated 99 EBOV genomes from 
infected patients in Sierra Leone. Upon examination of the 
specimens, investigators concluded that there is rapid mutation 
of the virus which could have implication for the development of 
diagnostics, vaccines, and therapies of the EBOV. It was observed 
that the sequence of the virus has changed since the start of 
the outbreak and the researchers have not found any additional 
zoonotic sources of the virus in the outbreak strains. Additionally, 
it was mentioned that the EBOV can affect approximately 20 000 
persons before it is contained[23]. Nonetheless, the typical 
symptoms seen in patients with the EBOV can be mistaken for 
other infectious diseases that are more common[2].
3. Transmission epidemiology
   A published article in 1995 reported that two control NHPs 
were infected with the ZEBOV without direct contact with 
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inoculated challenged monkeys held in the same room. The most 
likely source of transmission can be aerosol, oral, or conjunctival 
exposure secreted from the infected monkeys[24]. An experiment 
examined the transmission of the EBOV from pigs to NHPs 
without direct contact. The inoculated piglets were inoculated 
with ZEBOV and placed in a room containing four cynomolgus 
macaques. The NHPs were housed in two levels of individual 
cages within the pig pen and separated by wire mesh to prevent 
direct interaction. The cages housing the NHPs were located 
to the side of an air exhaust system. During the cleaning of the 
cages, piglets were removed and precautionary measures such 
as preventing the water from coming into contact with the NHPs 
cage and the changing of disposable glove between procedures 
and animals. However, the NHPs were infected with the EBOV 
and the EBOV antigen were found in the respiratory epithelial 
cells in the lung of the NHPs. Due to the measures taken, 
suggestive modes of transmission can be inhalation or droplets 
inoculated in the eyes. Therefore, in such an environment which 
prevents direct contact can lead to the concept of airborne 
transmission[3]. 
4. Vaccines research 
   Previously, the development of a vaccine for the EBOV was 
disputed because the disease was rare and many companies had 
little interest. Due to frequent outbreaks of the EBOV, this has 
drawn attention for vaccine and treatment development for the 
bio threat pathogen. The development of a protective vaccine 
is not only recommended or needed by medical workers, first 
responders; but also by affected population. Currently, there is no 
licensed or approved vaccine or therapeutics for the EBOV while 
the disease is spreading quickly[5]. However, the U.S. Food and 
Drug Administration advise the public that fraudulent drugs on 
the market claiming to prevent or treat the EBOV is false[25].
   The first attempt immunization process for the EBOV occurred 
in 1976, when an investigator accidently got pricked. The disease 
had similar features of the MARV as a result the investigator 
was given human interferon every 12 h for 14 d. The following 
morning, the patient temperature was normally but increased 
during the evening period. Therefore, dosage of convalescent 
serum was administered to the patient. However, no definite 
conclusion was made as to whether the serum administered was 
responsible for the results obtained[9]. The convalescent serum 
was extracted from Yambuku Ebola hemorrhagic fever epidemic 
in 1976 and the researcher survived[9,26]. In 1995, there was 
an outbreak of the EBOV in the Democratic Republic of the 
Congo[27]. A total of 316 cases of the Ebola were observed with 
an overall case fatality rate of 80%. A total of eight patients 
received blood transfusion from convalescent patients while only 
seven survived[28].
   Numerous researches in filovirus infection have been utilized in 
animal models such as mice, guinea pigs, hamsters and NHPs[10]. 
Examples of NHPs used in filoviral models are African green 
monkeys, hamadryas baboons, cynomolgus macaques, and 
rhesus macaques[29]. The animal models adapted will increase 
scientist understanding of the pathogenesis of Ebola and Marburg 
hemorrhagic virus because human specimens are limited. 
Since the symptoms observed in the animal model are similar 
to humans, this practice will be most useful in evaluating the 
efficacy of vaccines and treatments developed[10].
   Experimental vaccines and treatments must be deployed in 
clinical trials and it is required to meet the ethical guidelines 
for trials. Here are the following eight ethical principle for 
trials of an experimental treatment or vaccine: (a) collaborative 
partnership (involvement of the community in every aspect 
of the trials), (b) Social value (provide valid information and 
disseminate knowledge), (c) Scientific validity (feasible trials 
and randomly select patient with included supportive care), (d) 
Fair selection of study population (transparency in selection 
criteria), (e) Favorable risk-benefit ratio ( minimize potential risk 
factor associated with the trial), (f) Independent review (public 
accountability with reviews from international organization), 
(g) informed consent (acquired written or orally consent from 
participates) and (h) Respect for recruited participants and study 
communities (ensure confidentially of patients and compensation 
for injuries during the research trial[30].
   In early attempts to develop vaccines that can prevent the 
spread of the EBOV, animal models such as the guinea pigs or 
NHPs were vaccinated with formalin-fixed or heat-inactivated 
virion preparations[31]. The results were inconsistent; a study 
indicated that the guinea pigs were partially protected[32], while 
the other study revealed complete protection was attained from 
an inactivated EBOV vaccine in four of the five hamadryas 
baboons[33]. However, other studies have proven that the 
inactivated EBOV does not provide sufficient immunity against 
the lethal challenge administered to the hamadryas baboons[34]. 
The classical methods used were unsuccessful which led to the 
formulation of new vaccines, such as recombinant viral vector 
vaccines, DNA vaccines and virus-like particles (VLPs). The 
advantage of using the new approach: “more robust induction of 
both innate and adaptive immune responses, humoral as well as 
cellular, resulting in a better vaccines efficacy”[35]. 
5. Venezuelan equine encephalitis virus (VEEV)
   The VEEV replicons particles that express glycoprotein (GP) 
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or nuclear protein (NP) of EBOV genes, in combination or 
separate protected mice and guinea pigs from lethal dosage of 
the virus[36]. However, a study concluded that the EBOV NP-
expressing VEEV replicon alone protected mice not guinea pigs 
when immunized. Moreover, immunization with the expressing 
EBOV GP and NP, in combination or alone resulted in 
cynomolgus macagues not being protected from lethal infection 
of the EBOV[37]. A recent study revealed that the VEEV-based 
replicon particles provided protection against EBOV and Sudan 
Ebola virus (SUDV). However, the results obtained from this 
study are inconsistent and more research is needed[38].
6. Adenovirus vaccine
   The adenovirus vector vaccine has been used in the 
development of vaccine against Ebola and evaluated in NHP 
model. The adenovirus expressing ZEBOV with GP (Ad-ZGP) 
is proven to protect mice, guinea pigs and NHPs against the 
Zaire Ebola challenge[39,40]. In the earlier years, the EBOV 
GP-expressing adenovirus-based vaccines (ADV) 5 and 
EBOV NP- expressing ADV5 protected cynomolgus macaques 
100% against the virus challenge. This first generation of the 
ADV had one filovirus GP gene but the second generation 
ADV had the able to express multiple antigens on a single 
construct. When the second generation of the ADV, which 
expressed numerous filovirus GPs of EBOV, SUDV and 
MARV was administered to cynomolgus macaques inducted 
a 100% protection against the EBOV, SUDV and two strains 
of MARV[40]. Although the ADV is effective, there is a 
problem of pre-existing immunity of ADV which can limit 
the immunogenicity and clinical utility. Approximately, 60% 
of the general population and 85% of African population have 
the prevalence of antibody to ADV. For example: macaques 
showed no signs of protection from the lethal ebola challenge 
when they are pre-immunized and vaccinated with EBOV GP-
expressing ADV5. A phase I clinical trial showed that the 
adenovirus serotype 5 expressing ZEBOV and SEBOV GP 
were safe for humans[41].
7. DNA vaccine
   In a study conducted, EBOV DNA vaccine was successfully 
used in protecting mice and guinea pigs against the challenge. 
Another strategy used included four inoculation with DNA 
encoding ZEBOV GP and SEBOV GP, boost of adenovirus 5 
expressing ZEBOV GP resulted in a cross protection in NHPs 
EBOV challenge[36]. Currently, there are no licensed DNA 
vaccines for human use. However, DNA vaccines encoded 
with EBOV GP, SUDV GP, and EBOV NP had been used in a 
phase 1 clinical trial in human which has proven to be safe and 
immunogenic[42].
8. Vesicular stomatitis virus
   A single dosage of the vesicular stomatitis virus expressing 
EBOV GP generated complete protection of NHPs from 
homologous challenge but unsuccessfully for a heterologous 
SEBOV challenge[28]. One study has proved that EBOV GP 
expressed on the vesicular stomatitis virus vaccine, when 
is administrated orally or intranasal results in complete 
protection of the cynomolgus macaques from the Ebola 
challenge[43]. A multiple vaccine composed of the vesicular 
stomatitis virus expressing the GP of MARV, ZEBOV, and 
SEBOV generated complete protection in NHPs challenged 
with MARV, ZEBOV and SEBOV[44]. The vesicular stomatitis 
virus expressing EBOV GP was administered to mice 24 
h before infection, 1 or 24 h post-challenge, all the mice 
survived. In guinea pigs, the outcome was 67%, 83% and 
50% when administered prior to infection and 1 or 24 h post 
challenge, respectively. Furthermore, the importance of this 
vaccine post exposure is partially effective. In an experiment, 
NHPs infected with the homologous EBOV challenge was 
given the vesicular stomatitis virus expressing ZEBOV GP 
or SEBOV GP approximately 30 min after infection. The 
results indicated 50% and 100% protection from ZEBOV and 
SEBOV, respectively[45]. Moreover, an article published in 
2008, evaluated NHPs protection capability against an aerosol 
challenge of the ZEBOV. All the monkeys immunized with the 
vesicular stomatitis virus were protected but the control species 
succumbed to the virus[46]. 
9. VLPs
   VLPs mimic the structure of a virion but do not contain 
the genetic composition of an infectious virus. However, it is 
noninfectious and safer than replicating vaccines. The EBOV 
VLPs is expressed as GP, NP and VP40, usually in the presence 
of adjuvant. This was administered three times to NHPs which 
resulted in complete protection against the EBOV challenge. 
Another researcher examined the use of the ZEBOV vaccine 
without the VP40, the outcome concluded mice and guinea pigs 
were protected from the ZEBOV challenge. Furthermore, other 
vaccines such as the EBOV without VP30, an Fc portion of a 
human IgG fused to the EBOV GP have been studied in rodent 
models but more research is needed to determine the efficacy 
and safety of these vaccines in NHPs[36].
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10. Treatments
10.1. Recombinant nematode anticoagulant protein c2 
(rNAPc2) 
   Coagulation disorders are one of the significant aspects 
of filovirus infection. In the instance of a filoviral infection, 
the tissue exhibits an important role in triggering bleeding 
complication in NHPs. When the organs are affected, this 
results in coagulation inhibitor depletion which in turn causes 
dissemination intravascular coagulation. In the dissemination 
intravascular coagulation, the tissue factor (a substance present 
on a cell but not in contact with blood) combines with factor VII 
for clotting formation[47]. However, the rNAPc2 inhibits factor 
VII and the tissue factor whereby providing partial post exposure 
protection to rhesus macaques during a filovirus infection. The 
NHPs that were treated with rNAPc2 had a longer survival time 
than the untreated control. The rNAPc2 provides a mark increase 
in survival rate for a NHP that is 100% affected with the filovirus 
infection. Lastly, rNAPc2 can be useful in the fight against other 
viral hemorrhagic fevers because it targets the disease process. It 
can be referred to as having a suitable pharmacokinetic and safety 
profile in humans. However, the clinical efficacy of rNAPc2 
needs to be confirmed[48]. 
10.2. Recombinant human activated protein C (rhAPC)
   It was observed that EVD and severe sepsis had similar 
clinical features such as fever, increased production of tissue 
factor and elevated levels of nitric oxide. The most common 
factor prominent in severe sepsis was deficiency in protein C. 
However, patients having severe sepsis treated with rhAPC 
resulted in improved survival. Taking into account the similarity 
between sepsis and EVD, the investigators decided to use the 
same procedure for improving survival from EBOV. As a result, 
the investigators decided to use NHPs to test the theory[49]. The 
activated protein C is generated from protein C, it was recognized 
that infected NHPs have decreased level of protein C when 
infected with EBOV. This is because the infection targets protein 
C which is produced in the liver[48]. Therefore, experiments 
were conducted to demonstrate the efficiency of rhAPC in 
protecting NHPs from the EBOV. This resulted in 14 rhesus 
macaque infected with the lethal EBOV challenge and 11 were 
administered the rhAPC, 30-60 min after the challenge for 7 d. 
The outcome concluded that 2 out of 11 were protected from the 
lethal EBOV challenge. The survival rate in treated NHPs was 
prolonged than the untreated[50]. This product was created as a 
single dose post exposure treatment but since the treatment does 
not target the virus, there may be merit in analyzing the treatment 
in conjunction with a direct antiviral[38].
10.3. RNA interference (RNAi) 
   RNAi represents a powerful process which inhibits gene 
expression with a regulated enzyme-mediated process. RNAi 
has been used for a number of years in the prevention of viral 
replication against number of viruses such as the HIV-1, 
hepatitis B virus, influenza A virus and herpes viruses. The small 
interfering RNA targeted the polymerase L protein of the Zaire 
Ebola, which formulated a stable nucleic acid-lipid particle. This 
phenomenon protected the guinea pig shortly after infected with 
the EBOV. This treatment was then tested in rhesus macaques, 
which targeted EBOV L, VP24, and the VP35 formulated in 
stable nucleic acid-lipid particles. Eventually, three of the 
monkeys were given four doses and as a result two survived the 
infection. However, eleven monkeys were given seven doses 
and all survived the infection. The purpose of the investigation 
using the rhesus macaque model was to represent the worst case 
scenario such as accidental exposure of a laboratory worker or 
a first responder to a high dosage of the ZEBOV, which has 
occurred several times in the past. Generally, the progression of 
Ebola viral disease is slower in humans than in NHPs, suggesting 
that the therapeutic window could be larger in humans than 
infected rhesus macaques[50].
10.4. Phosphorodiamidate morpholino oligomers (PMOs)
   At the point in time, most researchers focused on therapeutic 
strategies that bolstered the host immune response or inhibiting 
viral replication. As a result, two researchers decided to use 
a different approach; a substance called PMO. PMO exerts a 
hindrance of gene translation by blocking ribosomal assembly. 
As such, the EBOV specific is combined with the PMO which 
targets the viral mRNA in acquiring the VP24 and VP35. This 
has resulted in the protection of mice in pre-exposure and post-
exposure from the lethal Ebola challenge[51]. Afterwards, AVI-
6002 was developed which is known as the combination of PMOs 
against EBOV VP24 and VP35 which is currently in phase I 
clinical trials. These PMOs, provided 30-60 min of post exposure, 
approximately more than 60% of rhesus macaques were protected 
from the Ebola infection. The PMO has been tested in humans 
and it was considered to be safe and can be produce in large 
amounts[52]. 
10.5. MB-003 monoclonal antibody cocktail
   Recently, antibodies have proven to be efficacious for post-
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exposure treatment against the EBOV in NHPs. Protection was 
seen in rhesus macaques when passive transfer of macaque 
hyperimmune globulin was inoculated 2 days post-exposure. 
Another case concluded that a cocktail of three murine 
monoclonal antibodies successfully provided 100% protection 
in cynomolgus macagues administered within the first day but 
48 h after, the cocktail provided 50% protection against the 
lethal EBOV challenge. Lastly, a mixture of three monoclonal 
antibodies (MB-003) produced in a plant called the Nicotiana 
benthamiana. This product provided 100% or 65% protection 
from the lethal Ebola challenge with no clinical manifestation, 
when administered 1 or 2 days post-exposure respectively[53].
10.6. ZMapp 
   ZMapp, being developed by Mapp Biopharmaceutical Inc., 
is an experimental treatment, for use with individuals infected 
with EBOV. It has not yet been tested in humans for safety or 
effectiveness. The product is a combination of three different 
monoclonal antibodies that bind to the protein of the EBOV. 
Previous experiments have demonstrated that antibodies are 
crucial for the survival of patients from the EBOV. Therefore, 
research was conducted to determine a treatment that was 
superior to both MB-003 and ZMab, which can be used in an 
outbreak among communities, health care workers and laboratory 
workers. The therapeutic treatment would be an upgraded 
antibody derived from MB-003 and ZMab. The study used 
a combination of ZMapp 1 (c13C6+c2G4+c4G7), ZMapp 2 
(c13C6+c1H3+c2G4) and Zmapp 3 (c13C6+c1H3+c4G7). The 
best results were in the following order: ZMapp 1 (4 out of 6 
survived), ZMapp 2 (3 out of 6 survived) and ZMapp 3 (1 out of 
6 survived). Eventually, the study proceeded to use ZMapp 1 and 
2 on rhesus macaques to demonstrate which one of the treatments 
was superior. The NHPs were administered ZMapp 1 (Group A) 
and 2 (Group B), three days post infection. There was a 100% 
survival rate in the Group A and 5 out of 6 survived in Group B. 
As a result, ZMapp 1 was carried forward to be tested in rhesus 
macaques with the trademark being Zmapp. All the animals 
with ZMapp survived the lethal challenge[54]. At the time of the 
review, ZMapp was not tested in humans but dosages were given 
to Ebola victims. Two American doctors and two Liberian health 
workers were administered the treatment and they did survive. 
Unfortunately, a priest and a Liberian doctor given the treatment 
died. Additionally, a fifth health worker is now being treated 
with ZMapp. However, there is limited supply of the treatment 
and it has been exhausted. It must be noted that ZMapp is an 
experimental therapeutic treatment that is currently undergoing 
investigation[55].
10.7. Other experimental treatments
   A potential vaccine developed is being used in a human trail 
with a total of 60 persons from the Oxford area in the United 
Kingdom. If the resulted outcome is proven successful, the 
vaccine would be tested with volunteers in Gambia and Mali. 
This procedure will account for the potential difference between 
the European and West African hemisphere. The researcher stated 
that the vaccine is safe because “the vaccine takes a gene from 
the Ebola and puts in it a virus Carrier”[56].
   The Chinese researchers have developed a JK-05 which 
is a micro-molecular chemical which was approved to be 
manufactured for emergency use only. It contains a RNA 
polymerase of the virus which inhibits the virus replication. The 
drug has proven to be successful in resisting the replication of the 
EBOV in animal and experimental testing. It has been tested for 
approximately five years and has passed clinical testing[57].
11. Discussion
   The EBOV causes a highly lethal hemorrhagic fever and 
the most dangerous specie is the Zaire Ebola (ZEBOV), with 
a mortality rate of 90%[5]. The most prominent reservoir for 
the EBOV is the fruit bat. When the virus was first identified 
in 1967 and over the years the number of strains increased 
to five species (ZEBOV, SEBOV, Cote d’Ivoire ebolavirus, 
BDBV, and REBOV)[9,10]. The symptoms of the EBOV can be 
mistaken for other diseases that are similar in nature[2]. The vast 
majority of persons at risk for the EBOV have been residents 
of rural Central Africa. Some of the reasons associated with 
outbreaks of the EBOV are limitation in health surveillance and 
inadequate preventative measures[10]. Recently, researchers have 
suggested that close contact with infected individual[19], and the 
latest possibly that the virus is airborne contributes to the high 
infectivity of the EBOV[3]. 
   Moreover, the strain of the virus identified in West Africa is 
completely different from the virus identified in the Democratic 
Republic of Congo confirming the fact that the virus was 
not transferred from West to Central Africa[22]. However, 
research has demonstrated that the EBOV has mutated over the 
years[23]. Different animal models such as mice, guinea pigs, 
hamsters and NHPs have been used to determine the efficacy 
and effectiveness of vaccines and treatments against the lethal 
EBOV[10]. Researchers have to develop models that accurately 
reflect diseases that affect humans. This is critical in order to 
understand the pathogenesis of the EBOV as there is limited 
access to human tissue. The most useful model that demonstrates 
similar symptoms that occurs in humans, such as shock and 
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hemorrhage is the NHPs. Therefore, this model is the most 
beneficial in evaluating the efficacy of vaccines and treatments 
being developed. However, the use of smaller animals is crucial 
for preliminary evaluation of vaccines and therapeutic treatments 
against the virus because of ethical concerns when dealing with 
NHPs. Additionally, the testing of experimental Ebola vaccine 
or treatment must be conducted in clinical trials, but when the 
trials are demonstrated it must comply with the standard ethical 
principles[30].
   Examples of candidate vaccines tested on animal models are 
the VEEV, vesicular stomatitis virus, DNA vaccine, adenovirus 
vector vaccine and VLPs. The following are pre-exposure 
vaccination: the adenovirus type 5, vesicular stomatitis virus, 
VLPs and the recombinant EBOV. The post exposure treatments 
include rNAPc2, RNAi, recombinant human activated protein, 
PMO, MB-003 antibody cocktail[10,38,39,42,43,50]. And hence, 
there are other treatments such as, ZMapp and JK-05[55,57].
   The ADV was used in the mouse and NHP model. It was 
able to protect mouse and NHP 100% from the EBOV with 
approximately two dosages[40]. According to the records on DNA 
vaccines, four injections were administered to mice and guinea 
pigs which resulted in 100% protection from the EBOV[42]. The 
candidate vaccine that has the potential of preventing the EBOV 
and as a post-exposure treatment in mouse, guinea pigs and NHP 
is the vesicular stomatitis virus vaccine with a 100% protection 
in the NHPs and mouse[45]. Additionally, the VLP has provided 
100% protection in NHPs and mouse with 2 to 3 dosages from 
the EBOV[36].
   The treatments rNAPc2 and recombinant human activated 
protein that were administered daily resulted in 33% and 20% 
protection in rhesus macaque respectively. On the other hand, 
the RNA treatment provides a percentage range of 25% to 100% 
protection according to the dosage administered to guinea pigs 
and NHPs. Moreover, the amount of dosage administered to 
guinea pigs will determine the percentage of protection observed 
in NHPs whereas providing a 100% protection in mouse[48-50]. 
Additionally, the PMO used as a post-exposure treatment showed 
promising efficacy in reducing the mortality of NHPs. The most 
recent treatments are the monoclonal antibody cocktail, ZMapp 
and JK-05. The monoclonal antibody cocktail is considered to be 
effective in protecting NHPs from the EBOV when administered 
post-exposure within 1 or 2 days of infection. The latest 
development of the experimental drug is ZMapp which has been 
administered to one nurse and two doctors. The patients were 
showing improvement but the product has not been distributed to 
the general public. However, ZMapp has already been exhausted 
and would need a couple of months in producing large quantity 
of this treatment. The Chinese government has a drug named 
JK-05 which has passed pre-clinical and clinical safety test but 
it is restricted for emergency cases only[55-57]. Lastly, there is 
no clinically approved vaccine available for humans but the 
population has been warned about fraudulent products being sold 
on the market.
12. Conclusion 
   The EBOV is significantly affecting a vast majority of 
persons in West Africa and much progress has been made 
in the understanding of the EBOV replication. Tremendous 
amount of experiments have been conducted to develop drugs 
and vaccines which can prevent the spread of this dreadful 
virus. Animal models such as mice, guinea pigs, hamsters and 
NHPs have been used to test the effectiveness or safety of the 
vaccines or drugs developed. Advances have been made in the 
development of drugs/vaccines for the EBOV but there is a need 
for more research in the development of a vaccine or drug that is 
efficacious to tackle all the various species of the EBOV.
Conflict of interest statement
   We declare that we have no conflict of interest.
References
[1]    Burki TK. USA focuses on Ebola vaccine but research gaps remain. 
Lancet 2011; 378(9789): 389.
[2]    MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: 
neglected tropical diseases? PLoS Negl Trop Dis 2012; 6(6): e1546.
[3]    Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, 
Kobinger G. Transmission of Ebola virus from pigs to non-human 
primates. Sci Rep 2012; 2: 811.
[4]    Wa n g  D ,  R a j a  N U ,  Tr u b ey  C M ,  J u o m p a n  LY,  L u o  M , 
Woraratanadharm J, et al. Development of a cAdVax-based bivalent 
Ebola virus vaccine that induces immune responses against both the 
Sudan and Zaire species of Ebola virus. J Virol 2006; 80(6): 2738-
2746. 
[5]    Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 
377: 849-862.
[6]    Baron RC, McCormick JB, Zubeir OA. Ebola virus disease in 
southern Sudan: hospital dissemination and intrafamilial spread. 
Bull World Health Organ 1983; 61(6): 997-1003. 
[7]    Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, et 
al. Virus nomenclature below the species level: a standardized 
nomenclature for natural variants of viruses assigned to the family 
Yitades Gebre et al./Asian Pac J Trop Biomed 2014; 4(12): 928-936 935
Filoviridae. Arch Virol 2013; 158(1): 301-311.
[8]    Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling 
PB, et al. Hemorrhagic fever viruses as biological weapons: medical 
and public health management. JAMA 2002; 287: 2391-2405.
[9]    Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus 
infection. Br Med J 1977; 2: 541-544.
[10]  Nakayama E, Saijo M. Animal models for Ebola and Marburg virus 
infections. Front Microbiol 2013; 4: 267.
[11]  Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/
International Study Team. Bull World Health Organ 1978; 56(2): 
247-270.
[12]  Cox NJ, McCormick JB, Johnson KM, Kiley MP. Evidence for two 
subtypes of Ebola virus based on oligonucleotide mapping of RNA. 
J Infect Dis 1983; 147(2): 272-275.
[13]  Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. 
Isolation and partial characterisation of a new strain of Ebola virus. 
Lancet 1995; 345(8960): 1271-1274.
[14]  Towner JS, Sealy TK, Khristova ML, Albariño CG, Conlan S, 
Reeder SA, et al. Newly discovered Ebola virus associated with 
hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008; 4(11): 
e1000212.
[15]  Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, 
Magassouba N, et al. Emergence of Zaire Ebola virus disease in 
Guinea—preliminary report. New Engl J Med 2014; 371: 1418-
1425.
[16]  Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy 
EM. Spatial and temporal patterns of Zaire ebolavirus antibody 
prevalence in the possible reservoir bat species. J Infect Dis 2007; 
196(Suppl 2): S176-S183.
[17]  Kuhl A, Hoffmann M, Muller MA, Munster VJ, Gnirb K, Kiene M, 
et al. Comparative analysis of Ebola virus glycoprotein interactions 
with human and bat cells. J Infect Dis 2011; 204(Suppl 3): S840-
S849.
[18]  World Health Organization. Information note: Ebola and food safety. 
Geneva: World Health Organization; 2014. [Online] Available from: 
http://www.who.int/csr/disease/ebola/note-ebola-food-safety/en/ 
[Accessed on 10th September, 2014]
[19]  Heymann DL.  Control of  communicable diseases manual. 
Washington: American Public Health Association; 2004, p. 180-182.
[20]  Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular 
stomatitis virus-based vaccines for prophylaxis and treatment of 
filovirus infections. J Bioterror Biodef 2011; doi: 10.4172/2157-
2526.S1-004S1(4). 
[21]  WHO Ebola Response Team. Ebola virus disease in West Africa-
the first 9 months of the epidemic and forward projections. N Engl J 
Med 2014; doi: 10.1056/NEJMoa1411100.
[22]  World Health Organization. Virological analysis: no link between 
Ebola outbreaks in West Africa and Democratic Republic of Congo. 
Geneva: World Health Organization; 2014. [Online] Available from: 
http://www.who.int/mediacentre/news/ebola/2-september-2014/en/ 
[Accessed 3rd September, 2014]
[23]  Vence T.  Ebola outbreak strains sequenced.  Ontario:  The 
Scientist; 2014. [Online] Available from: http://www.the-scientist.
com/?articles.view/articleNo/40896/title/Ebola-Outbreak-Strains-
Sequenced/ [Accessed on 9th September, 2014]
[24]  Jaax N, Jahrling P, Geisbert T, Geisbert J, Steele K, McKee K, et 
al. Transmission of Ebola virus (Zaire strain) to uninfected control 
monkeys in a biocontainment laboratory. Lancet 1995; 346(8991-
8992): 1669-1671.
[25]  U.S. Food and Drugs Administration. FDA warns consumers about 
fraudulent Ebola treatment products. Silver Spring: U.S. Food and 
Drugs Administration; 2014. [Online] Available from: http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm410086.
htm. [Accessed on 10th September, 2014]
[26]  Le Guenno B, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. 
Isolation and partial characterisation of a new strain of Ebola virus. 
Lancet 1995; 345: 1271-1274.
[27]  Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, 
Guimard Y, et al. Ebola hemorrhagic fever in Kikwit, Democratic 
Republic of the Congo: clinical observations in 103 patients. J Infect 
Dis 1999; 179 (Suppl 1): S1-S7.
[28]  Connolly BM, Steele KE, Davis KJ, Geisbert TW, Kell WM, Jaax 
NK, et al. Pathogenesis of experimental Ebola virus infection in 
guinea pigs. J Infect Dis 1999; 179(Suppl 1): S203-S217.
[29]  Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for 
Ebola and Marburg viruses. Dis Model Mech 2009; 2(1-2): 12-17.
[30]  Rid A, Emanuel EJ. Ethical considerations of experimental 
interventions in the Ebola outbreak. Lancet 2014; doi: 10.1016/
S0140-6736(14)61315-5.
[31]  Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling 
PB. Evaluation in nonhuman primates of vaccines against Ebola 
virus. Emerg Infect Dis 2002; 8(5): 503-507.
[32]  Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. 
Inactivated vaccine for Ebola virus efficacious in guineapig model. 
Lancet 1980; 2: 1294-1295.
[33]  Mikhailov VV, Borisevich IV, Chernikova NK, Potryvaeva NV, 
Krasnyanskii VP. [The evaluation in hamadryas baboons of the 
Yitades Gebre et al./Asian Pac J Trop Biomed 2014; 4(12): 928-936936
possibility for the specific prevention of Ebola fever]. Vopr Virusol 
1994; 39: 82-84. Russian. 
[34]  Chupurnov AA, Chernukhin IV, Ternovoĭ VA, Kudoiarova NM, 
Makhova M, Azaev M, et al. [Attempts to develop a vaccine against 
Ebola fever]. Vopr Virusol 1995; 40(6): 257-260. Russian.
[35]  de Wit E, Feldmann H, Munster VJ. Tackling Ebola: new insights 
into prophylactic and therapeutic intervention strategies. Genome 
Med 2011; 3(1): 5.
[36]  Nakayama E, Saijo M. Animal models for Ebola and Marburg virus 
infections. Front Microbiol 2013; 4: 267.
[37]  Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez 
A, et al. Recombinant RNA replicons derived from attenuated 
Venezuelan equine encephalitis virus protect guinea pigs and mice 
from Ebola hemorrhagic fever virus. Vaccine 2000; 19(1): 142-153.
[38]  Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, 
Smith DR, et al. Potential vaccines and post-exposure treatments 
for filovirus infections. Viruses 2012; 4(9): 1619-1650.
[39]  Sul l ivan NJ,  Sanchez A,  Rol l in  PE,  Yang ZY, Nabel  GJ. 
Development of a preventive vaccine for Ebola virus infection in 
primates. Nature 2000; 408: 605-609.
[40]  Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer 
M, et al. Accelerated vaccination for Ebola virus haemorrhagic 
fever in non-human primates. Nature 2003; 424: 681-684.
[41]  Ledgerwood JE , Costner P, Desai N, Holman L, Enama ME, 
Yamshchikov G, et al. A replication defective recombinant Ad5 
vaccine expressing Ebola virus GP is safe and immunogenic in 
healthy adults. Vaccine 2010; 29(2): 304-313.
[42]  Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup 
RA, et al. A DNA vaccine for Ebola virus is safe and immunogenic 
in a phase I clinical trial. Clin Vaccine Immunol 2006; 13(11): 
1267-1277.
[43]  Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, 
et al. Mucosal immunization of cynomolgus macaques with the 
VSVΔG/ZEBOVGP vaccine stimulates strong Ebola GP-specific 
immune responses. PLoS One 2009; 4(5): e5547.
[44]  Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, 
Hensley LE, Grolla A, et al. Single-Injection vaccine protects 
nonhuman primates against infection with Marburg virus and three 
species of Ebola virus. J Virol 2009; 83(14): 7296-7304.
[45]  Tuffs A. Experimental vaccine may have saved Hamburg scientist 
from Ebola fever. BMJ 2009; 338: b1223.
[46]  Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Reed DS, 
Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based 
vaccines protect nonhuman primates against aerosol challenge with 
Ebola and Marburg viruses. Vaccine 2008; 26(52): 6894-6900.
[47]  Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett 
R, et al. Lethal E. coli septic shock is prevented by blocking tissue 
factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
[48]  Geisbert T, Hensley LE, Jahrling PB, Larsen T, Geisbert, JB, Paragas 
J, et al. Treatment of Ebola virus infection with a recombinant 
inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. 
Lancet 2003; 362(9400): 1953-1958.
[49]  Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, 
et al. Recombinant human activated protein C for the post exposure 
treatment of Ebola hemorrhagic fever. J Infect Dis 2007; 196(Suppl 
2): S390-S399.
[50]  Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, 
et al. Postexposure protection of non-human primates against a lethal 
Ebola virus challenge with RNA interference: a proof-of-concept 
study. Lancet 2010; 375(9729): 1896-1905.
[51]  Warfield KL, Swenson DL, Olinger GG, Nichols DK, Pratt WD, 
Blouch R, et al. Gene-specific countermeasures against Ebola virus 
based on antisense phosphorodiamidate morpholino oligomers. PLoS 
Pathog 2006; 2(1): e1.
[52]  Warren TK, Warfield KL, Wells J, Swenson DL, Donner KS, Van 
Tongeren SA, et al. Advanced antisense therapies for postexposure 
protection against lethal filovirus infections. Nat Med 2010; 16(9): 
991-994.
[53]  Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, 
et al. Therapeutic intervention of Ebola virus infection in rhesus 
macaques with the MB-003 monoclonal antibody cocktail. Sci Transl 
Med 2013; doi: 10.1126/scitranslmed.3006608.
[54]  Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. 
Reversion of advanced Ebola virus disease in nonhuman primates 
with ZMapp. Nature 2014; 514(7520): 47-53.
[55]  Szabo L. Experimental Ebola drug cured 100% of monkeys 
tested. USA Today; 2014. [Online] Available from: http://www.
usatoday.com/story/news/nation/2014/08/29/ebola-zmapp-success-
monkeys/14793487/ [Accessed on 23rd September, 2014]
[56]  O’Neill E. Ebola vaccine to be trialled in oxford. Oxford: Cherwell; 
2014. [Online] Available from: http://www.cherwell.org/news/
town/2014/08/30/ebola-vaccine-to-be-trialled-in-oxford [Accessed 
on 2nd September, 2014]
[57]  Pinghui Z. Ebola virus drug approved on mainland for emergency 
use only. Hong Kong: South China Morning Post; 2014. [Online] 
Available from: http://www.scmp.com/news/china/article/1582834/
ebola-virus-approved-mainland-emergency-use-only [Accessed on 
2nd September, 2014]
